A consumer fraud class action will move forward in Illinois federal court against skin-care company Galderma Laboratories over allegations that its Differin line of acne treatments contains benzoyl peroxide, which can degrade into the carcinogenic compound benzene.
In a Sept. 17 opinion, U.S. District Judge Lindsay C. Jenkins for the Northern District of Illinois denied Galderma Laboratories’ motion to dismiss the Illinois Consumer Fraud and Deceptive Trade Practices Act (ICFA) claim brought by plaintiff Skylar Williams.
Williams argued that the presence of benzene in Differin indicated a failure by Galderma to comply with the Food and Drug Administration’s Good Manufacturing Practices, leading to the misbranding and adulteration of the drugs. For more details, the original article can be accessed here.